Patient reported outcomes among those taking pazopanib for metastatic renal cell carcinoma (mRCC) in a community oncology setting

IKCS

This study investigated the impact of pazopanib on mRCC patients’ health-related quality of life (HRQOL) in the US community oncology setting. Using real-world retrospective data, this study showed no change over time for HRQOL in mRCC patients after starting on pazopanib, suggesting that pazopanib treatment did not worsen HRQOL. 

Read More